Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Intrathecal (injected into the spinal fluid) DepoCyt
Pacira Ireland Limited
Meningeal Neoplasms
1 trial -
Iomeron 400 mgI/ml solution for injection
The George Institute
Thoracic neoplasm
1 trial -
Irinotecan liposomes combined with cisplatin/carboplatin
The First People's Hospital of Lianyungang
Neuroendocrine Tumors
1 trial -
Jejunostomy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
KANG FU PEN
The First People's Hospital of Lianyungang
Cervical Cancer
1 trial -
LORLATINIB
Pfizer Australia Pty Ltd
Lung cancer
1 trial -
Ledipasvir 90mg/Sofosbuvir 400 mg
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
METHADONE for Opioid use disorder (DSM-5); ch…
Disc Medicine
Opioid use disorder (DSM-5); chronic non-cancer pain (ICD-11).
1 trial -
MK-7902-015
Merck Sharp and Dohme
Advanced/Metastatic Gastroesophageal Adenocarcinoma
1 trial -
MORPHINE for Prostate cancer
Disc Medicine
Prostate cancer
1 trial -
MedPulser Electroporation with bleomycin
INOVIO PHARMACEUTICALS, INC.
Cancer
1 trial -
Medpulser electroporation with Bleomycin
INOVIO PHARMACEUTICALS, INC.
Head and Neck Cancer
2 trials -
NIVOLUMAB
Disc Medicine
Melanoma, Renal cell carcinoma
1 trial -
Niraparib
Takeda
Epithelial Ovarian Cancer
1 trial -
OBU-BC-II-206
The First People's Hospital of Lianyungang
HER2 Positive Breast Cancer
1 trial -
ONTAK (denileukin difitox, DAB389IL-2)
LIGAND PHARMACEUTICALS INC
Lymphoma, T-Cell, Cutaneous
1 trial -
OROS hydromorphone
Janssen Cilag International NV
Cancer Pain
1 trial -
OXALIPLATIN, CAPECITABINE
Disc Medicine
Locally advanced or metastatic gastro-intestinal carcinoma
1 trial -
Olutasidenib
RIGEL PHARMACEUTICALS INC
AML (Acute Myeloid Leukemia)
1 trial -
Oral prednisolone (30mg/day) for 28 days
Hospital Authority, Hong Kong
Esophageal Neoplasms
1 trial -
PEG-rhG-CSF
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cervical Cancer
1 trial -
PHARBEVACOL
Tour Hekla
1st line treatment for unresectable metastatic colorectal cancer
1 trial -
Pegylated liposomal doxorubicin
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Carcinoma, Non-Small-Cell Lung
1 trial -
Pluvicto 1 000 MBq/mL solution for injection/infusion
Novartis Pharmaceuticals
Prostate cancer
1 trial -
Pregabalin
Pfizer
Bone Neoplasms
1 trial -
Providence
The George Institute
Cervical cancer
1 trial -
RADAR-1 CRPC
Fondazione Telethon ETS
metastatic castration resistant prostate cancer without mutations of BRCA1/2 genes or unknown
1 trial -
RIBOCICLIB, Kisqali 200 mg film-coated tablets
The George Institute
Hormone receptor–positive (HRpos)/human epidermal growth factor receptor 2–negative (HER2neg) early breast cancer at risk of recurrence
1 trial -
Raltitrexed
The First People's Hospital of Lianyungang
Head and Neck Squamous Cell Carcinoma
1 trial -
Realgar-Indigo Naturalis Formulation Combined with Anlotinib
The First People's Hospital of Lianyungang
Platinum-resistant Ovarian Cancer (PROC)
1 trial -
Recombinant Human Adenovirus Type 5 injection
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
Ribociclib
Novartis Pharmaceuticals
Metastatic Breast Cancer
1 trial -
S-1
The First People's Hospital of Lianyungang
Pancreatic Cancer
1 trial -
SELECTIO-UC
Fondazione Telethon ETS
metastatic or locally advanced urothelial cancer
1 trial -
SELPERCATINIB, SELPERCATINIB
Eli Lilly Co.
Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;
1 trial -
SIS-reinforced anastomosis
Rocket Pharmaceuticals B.V.
Rectal Cancer
1 trial -
Sequential Icotinib Plus Chemotherapy
Betta Pharmaceuticals Co.,
EGFR Positive Non-small Cell Lung Cancer
1 trial -
Shenlingcao Oral Liquid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Carcinoma, Non-Small-Cell Lung
1 trial -
SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation
Ningbo Cancer Hospital
Gastroenteropancreatic neuroendocrine tumors
1 trial -
TAGRISSO 80 mg film-coated tablets
Disc Medicine
EGFR mutated locally advanced or metastatic non-small cell lung cancer
1 trial -
TAGRISSO 80 mg film-coated tablets
Disc Medicine
EGFR mutated locally advanced or metastatic non-small cell lung cancer
1 trial -
TAMOXIFEN
Disc Medicine
Breast cancer
1 trial -
TailorDose-II
The George Institute
Breast cancer female NOS
1 trial -
Talzenna 1 mg hard capsules
Disc Medicine
Breast cancer
1 trial -
Temozolomide
Monte Rosa Therapeutics
Brain Neoplasms, Malignant, Primary
1 trial -
Thalidomide
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Tislelizumab + cisplatin + paclitaxel
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.